Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 7/20 | 0.72 |
| ▸ | RAB9A | P51151 | 4/20 | 0.65 |
| ▸ | NPC1 | O15118 | 3/20 | 0.65 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.63 |
| ▸ | FAAH | O00519 | 1/20 | 0.62 |
| ▸ | BCHE | P06276 | 1/20 | 0.62 |
| ▸ | ACHE | P22303 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | HRH1 | P35367 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13149648 | 0.85 | NPC1 (0.74) | LTA4HRAB9ANPC1HRH3MEN1 | |
| SCHEMBL1899201 | 0.84 | LTA4H (1.00) | LTA4HRAB9ANPC1HRH3HRH1 | |
| SCHEMBL4214019 | 0.84 | NPC1 (0.58) | LTA4HRAB9ANPC1HRH3MEN1 | |
| SCHEMBL6658840 | 0.83 | RAB9A (0.86) | LTA4HRAB9ANPC1HRH3MAPK1 | |
| SCHEMBL14970484 | 0.83 | LTA4H (0.97) | LTA4HRAB9ANPC1HRH3HRH1 | |
| SCHEMBL12259234 | 0.82 | ALDH1A1 (0.82) | LTA4HHRH3MAPK1MEN1KMT2A | |
| SCHEMBL16026480 | 0.81 | KMT2A (0.50) | LTA4HRAB9ANPC1HRH3BCHE | |
| SCHEMBL11898739 | 0.80 | NPC1 (0.97) | LTA4HRAB9ANPC1HRH3HRH1 | |
| SCHEMBL16226080 | 0.80 | SIGMAR1 (0.78) | HRH3FAAHMAPK1KMT2A | |
| SCHEMBL27976215 | 0.80 | HRH3 (0.73) | LTA4HHRH3ACHEKCNH2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3512501-A1 | COMPOSITIONS WITH PERMEATION ENHANCERS FOR DRUG DELIVERY | Children's Medical Center Corporation (US) | 2019-07-24 | — | — | EP | claimed |
| EP-3331547-A1 | COMPOSITIONS WITH PERMEATION ENHANCERS FOR DRUG DELIVERY | Children's Medical Center Corporation (US) | 2018-06-13 | — | — | EP | claimed |
| WO-2018053140-A1 | COMPOSITIONS WITH PERMEATION ENHANCERS FOR DRUG DELIVERY | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2018-03-22 | — | — | WO | claimed |
| WO-2017024282-A1 | COMPOSITIONS WITH PERMEATION ENHANCERS FOR DRUG DELIVERY | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2017-02-09 | — | — | WO | claimed |
| US-12053527-B2 | Compositions with permeation enhancers for drug delivery | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2024-08-06 | — | — | US | disclosed |
| CN-108135967-B | Composition with penetration enhancer for drug delivery | 儿童医学中心公司 | 2022-06-28 | — | — | CN | disclosed |
| US-20220040309-A1 | COMPOSITIONS WITH PERMEATION ENHANCERS FOR DRUG DELIVERY | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-02-10 | — | — | US | disclosed |
| US-11110175-B2 | Compositions with permeation enhancers for drug delivery | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2021-09-07 | — | — | US | disclosed |
| US-20200138710-A1 | COMPOSITIONS WITH PERMEATION ENHANCERS FOR DRUG DELIVERY | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2020-05-07 | — | — | US | disclosed |
| EP-3512501-A1 | COMPOSITIONS WITH PERMEATION ENHANCERS FOR DRUG DELIVERY | Children's Medical Center Corporation (US) | 2019-07-24 | — | — | EP | disclosed |
| EP-3331547-A1 | COMPOSITIONS WITH PERMEATION ENHANCERS FOR DRUG DELIVERY | Children's Medical Center Corporation (US) | 2018-06-13 | — | — | EP | disclosed |
| WO-2018053140-A1 | COMPOSITIONS WITH PERMEATION ENHANCERS FOR DRUG DELIVERY | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2018-03-22 | — | — | WO | disclosed |
| WO-2017024282-A1 | COMPOSITIONS WITH PERMEATION ENHANCERS FOR DRUG DELIVERY | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2017-02-09 | — | — | WO | disclosed |
| US-20090105260-A1 | Molecules to Enhance Percutaneous Delivery and Methods for Discovery Therefor | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2009-04-23 | — | — | US | disclosed |
| US-20090105260-A1 | Molecules to Enhance Percutaneous Delivery and Methods for Discovery Therefor | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2009-04-23 | — | — | US | disclosed |
| US-20090105260-A1 | Molecules to Enhance Percutaneous Delivery and Methods for Discovery Therefor | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2009-04-23 | — | — | US | disclosed |
| WO-2006091297-A2 | MOLECULES TO ENHANCE PERCUTANEOUS DELIVERY AND METHODS FOR DISCOVERY THEREFOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-08-31 | — | — | WO | disclosed |
| US-20030139394-A1 | Dibenzodiazepine derivatives, their preparation and use | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11110175-B2 | Compositions with permeation enhancers for drug delivery | ABCB11, MMP1, SLC47A1 | LTA4H 203/4885RAB9A 2597/4885NPC1 527/4885 |
| US-12053527-B2 | Compositions with permeation enhancers for drug delivery | ABCB11, MMP1, SLC47A1 | LTA4H 203/4885RAB9A 2597/4885NPC1 527/4885 |
| US-20030139394-A1 | Dibenzodiazepine derivatives, their preparation and use | CYP1B1, DRD1, CYP1A1 | LTA4H 3161/4885RAB9A 1198/4885NPC1 969/4885 |
| US-20200138710-A1 | COMPOSITIONS WITH PERMEATION ENHANCERS FOR DRUG DELIVERY | ABCB11, CFTR, MMP1 | LTA4H 229/4885RAB9A 2090/4885NPC1 357/4885 |
| US-20090105260-A1 | Molecules to Enhance Percutaneous Delivery and Methods for Discovery Therefor | NOTUM, TRPV1, TRPV4 | LTA4H 263/4885RAB9A 4676/4885NPC1 285/4885 |
| US-20220040309-A1 | COMPOSITIONS WITH PERMEATION ENHANCERS FOR DRUG DELIVERY | ABCB11, MMP1, SLC47A1 | LTA4H 203/4885RAB9A 2597/4885NPC1 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.